Results 101 to 110 of about 39,275 (210)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration

Biomolecules
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity.
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, David Tweedie, Nigel H. Greig   +4 more
doaj   +1 more source

Insights into GLP-1 Receptor Activation with a Nonpeptide Agonist [PDF]

Biochemistry, 2020
Thomas F. Martinez, Joan Vaughan, Alan Saghatelian   +2 more
openaire   +4 more sources

Survodutide - Novel Anti Obesity Drug

JK Science
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity.
Irtiqa Ayani Rathore, Sana Malik, Amarjeet Singh, Vishal R Tandon, Annil Mahajan   +4 more
doaj  

Increasing Postpartum Use of GLP-1 Receptor Agonists

JAMA
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.
Bliddal, Mette, Nohmie, Gabra, Damkier, Per, Pottegård, Anton   +3 more
openaire   +3 more sources

Eyes on GLP-1 receptor agonists

Journal of the Foundations of Ophthalmology
Glucagon-like peptide-1 (GLP-1) receptor agonists, such tirzepatide and semaglutide, have evolved from specialised diabetes treatments to household brands in recent years. The UK's approach to obesity and type 2 diabetes has changed as a result of its powerful effects on appetite suppression, weight loss, and glycaemic management, with prescriptions ...
openaire   +1 more source

Advances in the treatment of type 2 diabetes: impact of dulaglutide

Diabetes, Metabolic Syndrome and Obesity, 2016
Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most ...
Thompson AM, Trujillo JM
doaj  

Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025). [PDF]

Cureus
Makkena HB.
europepmc   +1 more source

Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications. [PDF]

Curr Obes Rep
Lee J, You JH, Park HJ, Roh JL, Paek SH.
europepmc   +1 more source

Association of GLP-1 Receptor Agonist Use with Hypersomnolence: A Real-world Cohort Analysis. [PDF]

J Diabetes Metab Disord
Kamel-Abusalha L, Afifi AM, Dawoud A, Hayath Z, Bouso MF, Aguillon A, Assaly R.   +6 more
europepmc   +1 more source

Reduced Complications and Improved Survival With Postoperative GLP-1 Receptor Agonist Use Following Lumbar Arthrodesis. [PDF]

Global Spine J
Proffitt EB, Rice SW, Schiedo RM, Stauff MP.   +3 more
europepmc   +1 more source